SIAP
ZYNE

Sterling Investment Advisors (Pennsylvania)’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,000
Closed -$83K – 452
2019
Q3 		$83K Buy
11,000
+5,000
+83% +$56.4K 0.04% 162
2019
Q2 		$81K Buy
+6,000
New +$69.3K 0.04% 164

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s ZYNE Position: Q4 2019 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2019, closing a stake of 11,000 shares — an estimated $83K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in ZYNE in Q2 2019 and held it in 2 quarters. The position peaked at $83K in Q3 2019. 79 funds tracked by Wall St. Rank hold ZYNE as of Q4 2019.

  • Sterling Investment Advisors (Pennsylvania) reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2019 after selling out during the quarter.
  • Sterling Investment Advisors (Pennsylvania) sold 11,000 Zynerba Pharmaceuticals, Inc shares in Q4 2019, an estimated $83K.
  • Sterling Investment Advisors (Pennsylvania) first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2019 and held it in 2 quarters.
  • Sterling Investment Advisors (Pennsylvania)'s Zynerba Pharmaceuticals, Inc position peaked at $83K in Q3 2019.
  • 79 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2019.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q4 2019, filed 10 Feb 2020.